Miebo FDA Approval History
Last updated by Judith Stewart, BPharm on May 20, 2023.
FDA Approved: Yes (First approved May 18, 2023)
Brand name: Miebo
Generic name: perfluorohexyloctane
Dosage form: Ophthalmic Solution
Previous Name: NOV03
Company: Bausch & Lomb Inc.
Treatment for: Dry Eye Disease
Miebo (perfluorohexyloctane) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease.
- Dry eye disease is often caused by excessive tear evaporation due to an altered tear lipid layer, often associated with the clinical signs of Meibomian gland dysfunction (MGD). When the tear film is unstable, it triggers ocular surface desiccation, inflammation and damage to the ocular surface.
- Miebo contains perfluorohexyloctane, which works to treat dry eye disease by stabilizing the tear film lipid layer at the air-liquid interface to prevent excessive tear evaporation.
- Miebo is administered into each eye four times daily.
- Common ocular adverse reactions include blurred vision and eye redness.
Development timeline for Miebo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
